CTRE Stock Analysis: CareTrust REIT | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 9.502m USD | 12M Return: 47.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 114M
EPS Trend: 96.5%
Qual. Beats: 0
Rev. Trend: 92.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CareTrust REIT, Inc. (NYSE: CTRE) is a self-administered, publicly traded real estate investment trust focused on the ownership, acquisition, financing, development, and leasing of skilled nursing facilities (SNFs), senior housing communities, and other healthcare-related properties. The company leases its properties to independent operators under a triple-net lease structure, which is common among healthcare REITs and shifts most property-level operating costs to tenants.
As of December 31, 2025, CareTrusts portfolio consisted of 407 SNFs, senior housing communities, and other properties comprising approximately 37,628 operational beds and units across 32 U.S. states and the United Kingdom. The highest concentration of properties by rental income was located in California, the U.K., Texas, and Tennessee.
In addition to its owned property portfolio, CareTrust held other real estate-related investments, including preferred equity investments, real estate secured loans, mezzanine loans, and a financing receivable. The company was established and incorporated on October 29, 2013, and is headquartered in Dana Point, California. Like most REITs, CareTrust is generally required to distribute the majority of its taxable income to shareholders in the form of dividends.
- SNF acquisition pipeline fuels portfolio expansion and FFO growth
- Interest rate volatility pressures cap rates and borrowing costs
- California and UK tenant concentration raises operator default risk
| Net Income: 334.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.97 > 1.0 |
| NWC/Revenue: 30.25% < 20% (prev 257.2%; Δ -226.9% < -1%) |
| CFO/TA 0.08 > 3% & CFO 413.0m > Net Income 334.9m |
| Net Debt (671.4m) to EBITDA (494.8m): 1.36 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (224.0m) vs 12m ago 19.50% < -2% |
| Gross Margin: 73.78% > 18% (prev 94.62%; Δ -20.84% > 0.5%) |
| Asset Turnover: 10.26% > 50% (prev 6.34%; Δ 3.92% > 0%) |
| Interest Coverage Ratio: 8.08 > 6 (EBIT TTM 390.1m / Interest Expense TTM 48.3m) |
| A: 0.03 (Total Current Assets 330.2m - Total Current Liabilities 188.6m) / Total Assets 5.24b |
| B: -0.10 (Retained Earnings -500.0m / Total Assets 5.24b) |
| C: 0.09 (EBIT TTM 390.1m / Avg Total Assets 4.56b) |
| D: 3.81 (Book Value of Equity 4.13b / Total Liabilities 1.08b) |
| Altman-Z'' = 4.45 = AA |
As of July 18, 2026, the stock is trading at USD 42.88 with a total of 2,356,227 shares traded. Over the past week, the price has changed by +6.61%, over one month by +19.01%, over three months by +9.61% and over the past year by +47.24%.
Current recommended Stop Loss: 41.40 (which is 3.5% or 1.4 ATR below the current price).
CareTrust REIT has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy CTRE.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 45.3 | 5.7% |
P/E Trailing = 25.7821
P/E Forward = 21.322
P/S = 18.1829
P/B = 2.2997
P/EG = 1.26
Revenue TTM = 468.1m USD
EBIT TTM = 390.1m USD
EBITDA TTM = 494.8m USD
Long Term Debt = 894.6m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 894.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 671.4m USD (calculated: Debt 894.6m - CCE 223.2m)
Enterprise Value = 10.2b USD (9.50b + Debt 894.6m - CCE 223.2m)
Interest Coverage Ratio = 8.08 (Ebit TTM 390.1m / Interest Expense TTM 48.3m)
EV/FCF = 25.62x (Enterprise Value 10.2b / FCF TTM 397.1m)
FCF Yield = 3.90% (FCF TTM 397.1m / Enterprise Value 10.2b)
FCF Margin = 84.83% (FCF TTM 397.1m / Revenue TTM 468.1m)
Net Margin = 71.55% (Net Income TTM 334.9m / Revenue TTM 468.1m)
Gross Margin = 73.78% ((Revenue TTM 468.1m - Cost of Revenue TTM 122.7m) / Revenue TTM)
Gross Margin QoQ = 56.85% (prev 58.93%)
Tobins Q-Ratio = 1.94 (Enterprise Value 10.2b / Total Assets 5.24b)
Interest Expense / Debt = 5.40% (Interest Expense 48.3m / Debt 894.6m)
Taxrate = 2.13% (7.27m / 341.9m)
NOPAT = 381.9m (EBIT 390.1m * (1 - 2.13%))
Current Ratio = 1.75 (Total Current Assets 330.2m / Total Current Liabilities 188.6m)
Debt / Equity = 0.22 (Debt 894.6m / totalStockholderEquity, last quarter 4.13b)
Debt / EBITDA = 1.36 (Net Debt 671.4m / EBITDA 494.8m)
Debt / FCF = 1.69 (Net Debt 671.4m / FCF TTM 397.1m)
Total Stockholder Equity = 3.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.34% (Net Income 334.9m / Total Assets 5.24b)
RoE = 8.67% (Net Income TTM 334.9m / Total Stockholder Equity 3.87b)
RoCE = 8.20% (EBIT 390.1m / Capital Employed (Equity 3.87b + L.T.Debt 894.6m))
RoIC = 7.60% (NOPAT 381.9m / Invested Capital 5.03b)
WACC = 5.88% (E(9.50b)/V(10.4b) * Re(5.94%) + D(894.6m)/V(10.4b) * Rd(5.40%) * (1-Tc(0.02)))
Discount Rate = 5.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.29 | Cagr: 39.35%
[DCF] Terminal Value 77.97% ; FCFF base≈341.0m ; Y1≈390.9m ; Y5≈575.4m
[DCF] Fair Price = 33.81 (EV 8.66b - Net Debt 671.4m = Equity 7.99b / Shares 236.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.49 | EPS CAGR: 21.41% | SUE: -0.39 | # QB: 0
Revenue Correlation: 92.78 | Revenue CAGR: 35.80% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.39 | Chg30d=+3.84% | Revisions=+17% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.42 | Chg30d=+4.17% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=1.80 | Chg30d=+15.26% | Revisions=+40% | GrowthEPS=+33.0% | GrowthRev=+23.5%
EPS next Year (2027-12-31): EPS=1.74 | Chg30d=+2.62% | Revisions=+17% | GrowthEPS=-3.5% | GrowthRev=+17.3%
[Analyst] Revisions Ratio: +36% (up=8, down=3)